PE20180241A1 - Adenovirus oncolitico que codifica una proteina b7 - Google Patents
Adenovirus oncolitico que codifica una proteina b7Info
- Publication number
- PE20180241A1 PE20180241A1 PE2017002327A PE2017002327A PE20180241A1 PE 20180241 A1 PE20180241 A1 PE 20180241A1 PE 2017002327 A PE2017002327 A PE 2017002327A PE 2017002327 A PE2017002327 A PE 2017002327A PE 20180241 A1 PE20180241 A1 PE 20180241A1
- Authority
- PE
- Peru
- Prior art keywords
- protein
- virus
- oncolytic adenovirus
- compositions
- treatment
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 3
- 230000000174 oncolytic effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Abstract
La presente invencion se refiere a un adenovirus oncolitico de replicacion competente con selectividad para celulas cancerosas, en donde el adenovirus comprende un transgen bajo el control de un promotor endogeno al virus, en donde el transgen comprende una secuencia de ADN que codifica una proteina B7 o un fragmento activo de la misma, composiciones que comprenden los mismos, metodos para generar el virus, y uso del virus y composiciones en el tratamiento, particularmente en el tratamiento de cancer
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1507419.8A GB201507419D0 (en) | 2015-04-30 | 2015-04-30 | Virus |
GBGB1516936.0A GB201516936D0 (en) | 2015-09-24 | 2015-09-24 | Virus |
GBGB1522013.0A GB201522013D0 (en) | 2015-12-14 | 2015-12-14 | Virus |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180241A1 true PE20180241A1 (es) | 2018-01-31 |
Family
ID=56008588
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017002327A PE20180241A1 (es) | 2015-04-30 | 2016-04-29 | Adenovirus oncolitico que codifica una proteina b7 |
PE2018000519A PE20181140A1 (es) | 2015-04-30 | 2016-04-29 | Adenovirus oncolitico que codifica una proteina b7 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000519A PE20181140A1 (es) | 2015-04-30 | 2016-04-29 | Adenovirus oncolitico que codifica una proteina b7 |
Country Status (31)
Country | Link |
---|---|
US (6) | US11000559B2 (es) |
EP (2) | EP3391892A1 (es) |
JP (3) | JP6931229B2 (es) |
KR (3) | KR102643574B1 (es) |
CN (2) | CN108396015B (es) |
AU (3) | AU2016256582B2 (es) |
BR (2) | BR122018004815A2 (es) |
CA (1) | CA2984038C (es) |
CL (2) | CL2017002731A1 (es) |
CO (1) | CO2017010831A2 (es) |
CY (1) | CY1122833T1 (es) |
DK (1) | DK3288573T3 (es) |
EA (1) | EA037611B1 (es) |
ES (1) | ES2780366T3 (es) |
HK (1) | HK1249009A1 (es) |
HR (1) | HRP20200439T1 (es) |
HU (1) | HUE048320T2 (es) |
IL (3) | IL284375B (es) |
LT (1) | LT3288573T (es) |
MX (1) | MX2017013684A (es) |
MY (1) | MY183703A (es) |
PE (2) | PE20180241A1 (es) |
PH (1) | PH12017501942A1 (es) |
PL (1) | PL3288573T3 (es) |
PT (1) | PT3288573T (es) |
RS (1) | RS60105B1 (es) |
SA (2) | SA520412637B1 (es) |
SG (3) | SG10201901482XA (es) |
SI (1) | SI3288573T1 (es) |
WO (1) | WO2016174200A1 (es) |
ZA (1) | ZA201801589B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
RS60105B1 (sr) | 2015-04-30 | 2020-05-29 | Psioxus Therapeutics Ltd | Onkološki adenovirus kodiran proteinom b7 |
TW201722985A (zh) | 2015-11-02 | 2017-07-01 | 戊瑞治療有限公司 | Cd80胞外域多肽及其用於癌症治療 |
CN108697746A (zh) | 2015-12-17 | 2018-10-23 | 皮斯奥克斯治疗公司 | 编码抗tcr复合体抗体或片段的病毒 |
HRP20230197T1 (hr) * | 2016-03-31 | 2023-03-31 | The European Molecular Biology Laboratory | Nosači za dostavu izvedeni iz omotača adenovirusnog proteina |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
CA3035615A1 (en) | 2016-09-02 | 2018-03-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
JP7138946B2 (ja) * | 2016-09-27 | 2022-09-20 | セイター セラピューティクス エルエルシー | 最適化された腫瘍溶解性ウイルスおよびその使用 |
WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
AU2018215558B2 (en) * | 2017-02-03 | 2023-05-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
MX2019012849A (es) | 2017-04-28 | 2019-11-28 | Five Prime Therapeutics Inc | Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. |
CA3064897A1 (en) * | 2017-05-25 | 2018-11-29 | University Of Central Florida Research Foundation, Inc. | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
JP7216668B2 (ja) * | 2017-05-26 | 2023-02-01 | エピセントアールエックス,インコーポレイテッド | 導入遺伝子を保持する組換えアデノウイルス |
PT3630143T (pt) * | 2017-06-01 | 2023-08-29 | Akamis Bio Ltd | Vírus oncolítico e método |
WO2019147921A1 (en) * | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
WO2019173334A1 (en) * | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
CA3095427A1 (en) * | 2018-03-30 | 2019-10-03 | Tomoki Todo | Swelling-suppressive oncolytic virus |
JP2022502074A (ja) * | 2018-09-10 | 2022-01-11 | ジェネセイル バイオテック(シャンハイ)カンパニー リミテッド | 改変された腫瘍溶解性ウイルス、組成物、およびその使用 |
EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US20220249127A1 (en) * | 2019-05-14 | 2022-08-11 | Oncolys Biopharma Inc. | Method for administering oncolytic virus to tumor tissue, and device for administration |
GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
WO2023180527A1 (en) * | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3405241A1 (de) * | 1984-02-15 | 1985-08-29 | Bayer Ag, 5090 Leverkusen | 1-/4-(benzothia- oder -oxazol-2-ylthio- oder -2-yloxy) phenyl/-1,3,5-triazin-2,4,6-(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
KR920008907B1 (ko) * | 1989-11-28 | 1992-10-10 | 삼성전자 주식회사 | 파우어 온/오프시 화면 크기 제어회로 |
US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
HU216871B (hu) | 1993-07-13 | 1999-09-28 | Rhone-Poulenc Rorer S.A. | Defektív adenovírusvektorok és génterápiai alkalmazásuk |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
DE69838510T2 (de) | 1997-02-20 | 2008-07-03 | Johns Hopkins University School Of Medicine | Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren |
US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
EP1112372A1 (en) * | 1998-09-11 | 2001-07-04 | Genvec, Inc. | Alternatively targeted adenovirus |
CA2678259C (en) * | 1998-12-09 | 2016-10-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
PT1550722E (pt) | 1999-05-17 | 2007-09-25 | Crucell Holland Bv | ''adenovírus humano recombinante do serótipo 35'' |
ATE291633T1 (de) | 1999-06-01 | 2005-04-15 | Univ Washington | Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration |
US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
WO2001053505A2 (en) | 2000-01-21 | 2001-07-26 | Biovex Limited | Herpes virus strains for gene therapy |
US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
JP2003534806A (ja) | 2000-05-31 | 2003-11-25 | ジェンベク、インコーポレイティッド | アデノウイルスベクターのターゲティングの方法および組成物 |
DE60234496D1 (de) | 2001-01-04 | 2010-01-07 | Goeran Wadell | Virusvektor zur gentherapie |
US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
EP1470233A1 (en) | 2002-02-01 | 2004-10-27 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
CN1705740B (zh) * | 2002-10-15 | 2013-07-24 | 佩尔·松内·霍尔姆 | 具有反向基因表达的腺病毒及其应用 |
US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
US20050136035A1 (en) | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
AU2004260044B2 (en) | 2003-07-18 | 2009-04-23 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
KR101169109B1 (ko) | 2004-05-26 | 2012-07-26 | 싸이오서스 테라퓨틱스 엘티디. | 암 치료에 사용하기 위한 키메릭 아데노바이러스 |
CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
US20060292682A1 (en) * | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
CN101068933A (zh) * | 2004-08-25 | 2007-11-07 | 细胞基因系统有限公司 | 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体 |
EP1784493A2 (en) * | 2004-09-01 | 2007-05-16 | The Government of the United States of America as Represented by The Department of Health and Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
WO2006060314A2 (en) | 2004-12-01 | 2006-06-08 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
JP2009505680A (ja) | 2005-08-31 | 2009-02-12 | ジェンベク、インコーポレイティッド | アデノウイルスベクターに基づくマラリアワクチン |
DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
US20110086005A1 (en) | 2008-05-27 | 2011-04-14 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
CN101381742A (zh) * | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
US20120283318A1 (en) * | 2009-10-05 | 2012-11-08 | Mei Ya-Fang | Replicating viral vectors for gene therapy |
CN107090440B (zh) | 2010-08-16 | 2021-10-22 | 萨克生物研究学院 | 腺病毒组装方法 |
CN103221423B (zh) * | 2010-09-24 | 2015-09-30 | 昂克斯治疗有限公司 | 溶瘤腺病毒载体及与其相关的方法和用途 |
EP2619312A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
JP2015507604A (ja) | 2011-11-14 | 2015-03-12 | リジェネレイティブ サイエンシーズ, エルエルシー | 懸濁粒子送達システムおよび方法 |
CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
WO2014138314A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
KR20160137946A (ko) | 2013-11-22 | 2016-12-02 | 디엔에이트릭스, 인코포레이티드 | 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스 |
GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
GB201510197D0 (en) * | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
WO2016146894A1 (en) | 2015-03-17 | 2016-09-22 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
RS60105B1 (sr) | 2015-04-30 | 2020-05-29 | Psioxus Therapeutics Ltd | Onkološki adenovirus kodiran proteinom b7 |
CN108697746A (zh) | 2015-12-17 | 2018-10-23 | 皮斯奥克斯治疗公司 | 编码抗tcr复合体抗体或片段的病毒 |
WO2017161360A2 (en) | 2016-03-18 | 2017-09-21 | Nant Holdings Ip, Llc | Multimodal vector for dendritic cell infection |
US20190194690A1 (en) | 2016-08-29 | 2019-06-27 | Psioxus Therapeutics Limited | Adenovirus armed with bispecific t cell engager (bite) |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
EP3872180A1 (en) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
PT3630143T (pt) * | 2017-06-01 | 2023-08-29 | Akamis Bio Ltd | Vírus oncolítico e método |
GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-04-29 RS RS20200325A patent/RS60105B1/sr unknown
- 2016-04-29 CN CN201810213204.1A patent/CN108396015B/zh active Active
- 2016-04-29 HU HUE16723043A patent/HUE048320T2/hu unknown
- 2016-04-29 SI SI201630679T patent/SI3288573T1/sl unknown
- 2016-04-29 PT PT167230432T patent/PT3288573T/pt unknown
- 2016-04-29 EP EP18159326.0A patent/EP3391892A1/en active Pending
- 2016-04-29 JP JP2017552966A patent/JP6931229B2/ja active Active
- 2016-04-29 IL IL284375A patent/IL284375B/en unknown
- 2016-04-29 BR BR122018004815A patent/BR122018004815A2/pt not_active Application Discontinuation
- 2016-04-29 WO PCT/EP2016/059609 patent/WO2016174200A1/en active Application Filing
- 2016-04-29 BR BR112017023171-9A patent/BR112017023171A2/pt active Search and Examination
- 2016-04-29 EA EA201791971A patent/EA037611B1/ru unknown
- 2016-04-29 US US15/570,100 patent/US11000559B2/en active Active
- 2016-04-29 ES ES16723043T patent/ES2780366T3/es active Active
- 2016-04-29 DK DK16723043.2T patent/DK3288573T3/da active
- 2016-04-29 KR KR1020177032425A patent/KR102643574B1/ko active IP Right Grant
- 2016-04-29 EP EP16723043.2A patent/EP3288573B1/en active Active
- 2016-04-29 PL PL16723043T patent/PL3288573T3/pl unknown
- 2016-04-29 SG SG10201901482XA patent/SG10201901482XA/en unknown
- 2016-04-29 SG SG10201803081TA patent/SG10201803081TA/en unknown
- 2016-04-29 CN CN201680024692.0A patent/CN107690479B/zh active Active
- 2016-04-29 LT LTEP16723043.2T patent/LT3288573T/lt unknown
- 2016-04-29 KR KR1020187030538A patent/KR20180118249A/ko active Application Filing
- 2016-04-29 MX MX2017013684A patent/MX2017013684A/es unknown
- 2016-04-29 MY MYPI2017703967A patent/MY183703A/en unknown
- 2016-04-29 SG SG11201708604TA patent/SG11201708604TA/en unknown
- 2016-04-29 PE PE2017002327A patent/PE20180241A1/es unknown
- 2016-04-29 AU AU2016256582A patent/AU2016256582B2/en active Active
- 2016-04-29 CA CA2984038A patent/CA2984038C/en active Active
- 2016-04-29 PE PE2018000519A patent/PE20181140A1/es unknown
- 2016-04-29 KR KR1020247006825A patent/KR20240032177A/ko not_active Application Discontinuation
- 2016-08-08 US US15/231,422 patent/US10124028B2/en active Active
-
2017
- 2017-05-03 US US15/586,091 patent/US10548929B2/en active Active
- 2017-10-25 CO CONC2017/0010831A patent/CO2017010831A2/es unknown
- 2017-10-25 PH PH12017501942A patent/PH12017501942A1/en unknown
- 2017-10-26 IL IL255286A patent/IL255286B/en active IP Right Grant
- 2017-10-26 CL CL2017002731A patent/CL2017002731A1/es unknown
- 2017-10-30 SA SA520412637A patent/SA520412637B1/ar unknown
- 2017-10-30 SA SA517390260A patent/SA517390260B1/ar unknown
- 2017-10-31 US US15/799,644 patent/US10322152B2/en active Active
-
2018
- 2018-02-28 AU AU2018201446A patent/AU2018201446B2/en active Active
- 2018-03-05 CL CL2018000587A patent/CL2018000587A1/es unknown
- 2018-03-07 ZA ZA201801589A patent/ZA201801589B/en unknown
- 2018-03-08 JP JP2018041788A patent/JP6928380B2/ja active Active
- 2018-03-12 IL IL258044A patent/IL258044B/en unknown
- 2018-06-20 HK HK18107929.1A patent/HK1249009A1/zh unknown
- 2018-09-18 US US16/134,704 patent/US10849945B2/en active Active
-
2020
- 2020-03-17 HR HRP20200439TT patent/HRP20200439T1/hr unknown
- 2020-03-18 CY CY20201100253T patent/CY1122833T1/el unknown
- 2020-08-25 AU AU2020223665A patent/AU2020223665A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/301,502 patent/US20210338753A1/en not_active Abandoned
- 2021-08-05 JP JP2021129196A patent/JP7162929B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181140A1 (es) | Adenovirus oncolitico que codifica una proteina b7 | |
CO2018005945A2 (es) | Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este | |
PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
CL2023000165A1 (es) | Novedosas proteínas de la cápside del virus adenoasociado | |
CL2018001107A1 (es) | Variantes del factor viii cpg reducido, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasis. | |
UY35964A (es) | Anticuerpos humanos para pd?1 | |
CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
AR100419A1 (es) | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico | |
BR112018013930A2 (pt) | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus | |
PE20160244A1 (es) | Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos | |
CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
PE20181206A1 (es) | Construcciones especificas del higado, casetes de expresion del factor viii y metodos de uso de estos | |
UY35965A (es) | Anticuerpos humanos contra pd?l1 | |
AR102527A1 (es) | Vacunas terapéuticas para hpv16 | |
CL2015003199A1 (es) | Peptidos terapeuticos | |
BR112019002646A2 (pt) | composições de poxvírus quimérico e usos das mesmas | |
MX2019006722A (es) | Construcciones de adenovirus de chimpance con antigenos de lyssavirus. | |
BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos | |
UY35718A (es) | Anticuerpos anti-csf-1r: métodos de expresión de los mismos. | |
UY35703A (es) | Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos | |
CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
AR102301A1 (es) | Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros | |
UY36678A (es) | Anticuerpos anti-fcrn. | |
CL2016002492A1 (es) | Formulaciones de factor viii estables con bajo tenor de azúcar - glicina. | |
EA201890595A1 (ru) | Онколитический аденовирус, кодирующий белок b7 |